Clin2
NCT01050504Possibly a fitRecruiting

Donate blood and tissue to study recurrent or metastatic cancers

Localized Renal Pelvis and Ureter Urothelial CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft TissuesMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRecurrent Bladder CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Pelvis and Ureter Urothelial Carcinoma

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,500 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have prostate cancer or bladder/urothelial cancer that is locally recurrent or has spread to nearby areas or distant sites
  • There is a tumor spot in bone or soft tissue that can be safely biopsied, or you have surgery/procedures where extra tissue can be taken with minimal added risk
  • Your blood counts are high enough: platelets above 50,000, white blood cells above 1,500, and hemoglobin above 8
  • Blood clotting tests are within limits (INR under 1.5, PTT under 45)
  • You can understand the study and sign informed consent
  • You should not have a history of unexplained excessive bleeding after previous procedures

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05987241Recruiting· Phase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery

This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.

Phoenix, Arizona
NCT06109857Recruiting
Bladder Bank: Collecting samples for research

This study collects urine and tissue samples from people being checked for blood in their urine (hematuria) to build a 'bladder bank' for future research. By donating samples, you help scientists learn more about bladder conditions and improve diagnosis.

Rochester, Minnesota
NCT00026884Recruiting
Blood and tissue sample collection for cancer research

This study collects blood and tissue samples from people with cancer or suspected cancer, or from their blood relatives. Researchers use these samples to better understand cancer and develop new treatments.

Bethesda, Maryland
NCT02379429Recruiting
Collecting bladder/urothelial cancer tissue for future research

This study looks at urothelial cancer (often bladder cancer) samples taken during diagnosis or standard treatment. It may help researchers better understand the disease by using tissue that doctors already need to collect for care.

Bethesda, Maryland
NCT03973671Recruiting
Collecting blood and tissue samples during bladder cancer surgery

This study collects clinical and tissue samples from people who are having surgery for bladder cancer and related urinary-tract tumors. It aims to improve understanding of cancer and may help future care by building a large research dataset.

Leuven, Vlaams-Brabant
NCT07789119Not yet recruiting
Biospecimen collection for bladder and urinary tract cancers

This study collects samples (blood, urine, tissue) and health information from people with bladder or urinary tract cancers. The goal is to learn more about these cancers to improve detection and treatment in the future.

Houston, Texas

Hear when a new Malignant Solid Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.